Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cephalon

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

- PMLiVE

Sage surges after depression drug gets rapid path to approval

Will be able to file a marketing application based on its phase II trial

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

Teva cuts 25% of workforce, with Israel taking a heavy toll

But share prices increase by almost 14%

- PMLiVE

Teva sheds R&D chief after new CEO takes the helm

Kåre Schultz begins remoulding the Israeli pharma firm

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Mental health in the workplace

Mental health in the workplace

One in five people in the workplace will experience a mental health condition. Learn to spot the signs and the steps that you can take to care for yourself and...

Porterhouse Medical Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links